Oppenheimer Reiterates Outperform Rating on Coherus Biosciences (CHRS): "buying opportunity ahead of key catalysts"

March 10, 2026 8:15 AM

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $10.00 price target on Coherus Biosciences (NASDAQ: CHRS)The analyst commented, "CHRS ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found